Trial Profile
A Phase I Study of CPI-613 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane) for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2022
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 02 Jul 2022 Results presented at the 24th World Congress on Gastrointestinal Cancer
- 27 Jun 2022 Results published in the Cornerstone Pharmaceuticals Inc Media Release.
- 27 Jun 2022 According to a Cornerstone Pharmaceuticals Inc media release, data from the study will be presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022.